Background: Glioblastoma multiforme (GBM) is the most common and lethal primary
malignancy of the central nervous system (CNS). Despite the proven benefit of surgical …

Glioblastoma multiforme (GBM) is commonly known as the most aggressive primary CNS
tumor in adults. The mean survival of it is 14 to 15 months, following the standard therapy …

Current glioblastoma therapies are insufficient to prevent tumor recurrence and eventual
death. Here, we describe a method to treat malignant glioma by nonviral DNA delivery using …

Glioblastoma (GBM) is the most prevalent primary brain tumor and ranks among the most
lethal of human cancers with conventional therapy offering only palliation. Great strides have …

Glioblastoma (GBM) is the most common and aggressive primary brain tumor in the adult
population and it carries a dismal prognosis. Inefficient drug delivery across the blood brain …

Glioblastoma multiforme (GBM) is one of the most lethal cancers with a poor prognosis. Over
the past century since its initial discovery and medical description, the development of …

Glioblastoma multiforme (GBM) is one of the highly malignant brain tumors characterized by
significant morbidity and mortality. Despite the recent advancements in the treatment of …

Glioma accounts for the majority of human brain tumors. With prevailing treatment regimens,
the patients have poor survival rates. In spite of current development in mainstream glioma …

Gene transfer is an increasingly utilized approach for research and clinical applications
involving the central nervous system (CNS). Vectors for gene transfer can be as simple as …

The preclinical and clinical development of novel immunotherapies for the treatment of
central nervous system (CNS) tumors is advancing at a rapid pace. High-grade gliomas …